405亿美元天坑交易后,梯瓦从仿制药转向创新之路

MedTrend医趋势
06 Jun

十年前,梯瓦制药(Teva Pharmaceutical)因一笔高达405亿美元的交易几乎危及了其百年基业。2015年7月,梯瓦宣布以405亿美元收购艾尔建(Allergan)的仿制药业务,从而成为全球最大仿制药企业。时任首席执行官埃雷兹·维戈德曼(Erez Vigodman)将这笔交易誉为“为梯瓦股东创造引人注目的可持续价值的绝佳机会”。然而,与许多大型并购案例相似,结果并未如预期般顺利。梯瓦在...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10